Astrazeneca Pharma India Achieves All-Time High, Reflecting Strong Market Performance

Astrazeneca Pharma India has reached a significant milestone today, hitting an all-time high of Rs. 10,050. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector. Despite a slight underperformance of -0.36% today compared to the Sensex's -0.12%, Astrazeneca has shown remarkable growth over the past year, boasting a 58.82% increase, significantly outpacing the Sensex's 8.35%.
The stock has been part of the MomentumNow and MOJO Stocks on MarketsMOJO since early March 2025, reflecting its robust market position. Astrazeneca's financial metrics are impressive, with a net profit growth of 88.82% reported in March 2025 and a record net sales figure of Rs. 480.48 crore. The company also maintains a low debt-to-equity ratio, indicating strong management efficiency with a return on equity (ROE) of 19.06%.

Over the last three years, Astrazeneca has consistently delivered returns, outperforming the BSE 500 in each annual period. While the stock has experienced high volatility today, trading above its moving averages, it remains a notable player in the large-cap segment, ranked 26th among its peers.